To create a novel brain metastasis severity score (Metastatic Brain Lesion Score - MBLS) for predicting postoperative mortality at 90 days in patients undergoing craniotomy for brain metastases, highlighting its significance in clinical practice.
Key Findings:
Age at surgery, reduced functional status, use of chronic pain medicine, presence of deep brain nucleus/brainstem lesions, and hemorrhage in metastases were significantly associated with 90-day mortality. The MBLS was developed based on these significant predictors identified through multivariable analysis, offering a more tailored risk assessment.
Interpretation:
The MBLS may provide a more tailored risk assessment for patients with brain metastases undergoing craniotomy compared to existing general surgical risk scores, potentially improving patient outcomes.
Limitations:
The study is retrospective and conducted at a single institution, which may limit generalizability and external validity.
Potential biases in patient selection and data collection may affect the results.
Conclusion:
The MBLS is a promising tool for predicting 90-day postoperative survival in brain metastasis patients, potentially improving patient selection and outcomes in clinical practice.
by Daniel C. Kreatsoulas, Joanne Kim, Mark Damante, Anna Orr, Joshua Wang, Joshua Vignolles-Jeong, Maxwell Gruber, Varun Shah, Nicholas Musgrave, Russell Lonser, Daniel Prevedello, J. Bradley Elder, Douglas A. Hardesty
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from March 16 - 31.
A Keck Medicine of USC neurointerventionalist discusses how a minimally invasive, endovascularly implantable cerebrospinal fluid shunt is the next-generation treatment for normal pressure hydrocephalus — and possibly more.
